Hua Yang

Hua Yang currently serves as the Senior Vice President of Nonclinical Development. She holds a PhD in Pharmacokinetics from the University of Nebraska Medical Center, complemented by a BA in Pharmacology from Fudan University and an MS in Pharmacology from Peking Union Medical School. Previously, Yang was the Vice President of DMPK and Clinical Pharmacology at Agios Pharmaceuticals, where she played a pivotal role in the development and FDA approval of IDHIFA (enasidenib) for relapsed or refractory acute myeloid leukemia (AML) and TIBSOVO (ivosidenib) for AML patients with IDH1 mutations. Before her tenure at Agios Pharmaceuticals, she held key positions in DMPK and drug discovery at Millennium/Takeda Pharmaceuticals and Bristol-Myers Squibb, contributing to several drug development projects.